Osteologix, Inc. (OTC BB: OLGX), a specialty biopharmaceutical company, has dedicated their efforts to improving the health of those afflicted with musculoskeletal diseases through the development of innovative therapies. NB S101, the company’s lead investigational product candidate, is an innovative pharmaceutical agent designed to treat and prevent osteoporosis. Their mission is to partner with the healthcare community to apply new scientific information to the development of beneficial products. For more information please visit www.osteologix.com.
- 17 years ago
QualityStocks
Osteologix, Inc. (OTC BB: OLGX)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Massimo Group (NASDAQ: MAMO) Ramps Up Innovation, Logistics to Power Growth
Massimo (NASDAQ: MAMO) is making strategic moves to actively enhance its position in the powersports and…
-
QualityStocksNewsBreaks – Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF) Unveils Significant Resource Estimate at Storm Copper Project
Aston Bay (TSX.V: BAY) (OTCQB: ATBHF), a mineral exploration company focused on high-grade metals deposits,…
-
SolarBank Corp. (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) Expands Portfolio with Additional Solar Project in Upstate New York
SolarBank is developing a 4.584 MW DC ground-mount solar project in upstate New York, projected…